SrasV1, PascalFrancis, Corpus, bibRecord, 000176

Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a

Identifieur interne : 000176 ( PascalFrancis/Corpus ); précédent : 000175; suivant : 000177

Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a

Auteurs : Shunsuke Kohyama ; Satoshi Ohno ; Tatsuya Suda ; Maiko Taneichi ; Shoichi Yokoyama ; Masahito Mori ; Akiharu Kobavashi ; Hidenori Havashi ; Tetsuva Uchida ; Masanori Matsui

Source :

Antiviral research [ 0166-3542 ] ; 2009.

RBID : Pascal:09-0466845

Descripteurs français

Pascal (Inist)
- Induction, Lymphocyte T cytotoxique, Syndrome respiratoire aigu sévère, Virus syndrome respiratoire aigu sévère, Immunisation, Vaccin, Vaccination, Liposome, Polyprotéine, Prévention, Immunoprophylaxie, Immunité cellulaire, Composé conjugué, Protéine non structurale.

English descriptors

KwdEn :
- Cellular immunity, Conjugated compound, Cytotoxic T lymphocyte, Immunization, Immunoprophylaxis, Induction, Liposome, Polyprotein, Prevention, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Vaccination, Vaccine.

Abstract

Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A^*0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8⁺ T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8⁺ T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A^*0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 84`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a`
A11	`01`	`1`		`@1 KOHYAMA (Shunsuke)`
A11	`02`	`1`		`@1 OHNO (Satoshi)`
A11	`03`	`1`		`@1 SUDA (Tatsuya)`
A11	`04`	`1`		`@1 TANEICHI (Maiko)`
A11	`05`	`1`		`@1 YOKOYAMA (Shoichi)`
A11	`06`	`1`		`@1 MORI (Masahito)`
A11	`07`	`1`		`@1 KOBAVASHI (Akiharu)`
A11	`08`	`1`		`@1 HAVASHI (Hidenori)`
A11	`09`	`1`		`@1 UCHIDA (Tetsuva)`
A11	`10`	`1`		`@1 MATSUI (Masanori)`
A14	`01`			`@1 Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho @2 Iruma-gun, Saitama 350-0495 @3 JPN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 10 aut.`
A14	`02`			`@1 Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University @2 Sakado-city, Saitama 350-0295 @3 JPN @Z 1 aut. @Z 2 aut. @Z 8 aut.`
A14	`03`			`@1 Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases @2 Musashimurayama-city, Tokyo 208-0011 @3 JPN @Z 4 aut. @Z 9 aut.`
A14	`04`			`@1 Drug Delivery System Development Division, Nippon Oil and Fat Corporation @2 Tokyo 150-6019 @3 JPN @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 168-177`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000170327240070`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.`
A47	`01`	`1`		`@0 09-0466845`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A^0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8⁺ T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8⁺ T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A^0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.
C02	`01`	`X`		`@0 002B02S05`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Induction @5 01`
C03	`01`	`X`	`ENG`	`@0 Induction @5 01`
C03	`01`	`X`	`SPA`	`@0 Inducción @5 01`
C03	`02`	`X`	`FRE`	`@0 Lymphocyte T cytotoxique @5 02`
C03	`02`	`X`	`ENG`	`@0 Cytotoxic T lymphocyte @5 02`
C03	`02`	`X`	`SPA`	`@0 Linfocito T citotóxico @5 02`
C03	`03`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 04`
C03	`04`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 04`
C03	`04`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 04`
C03	`05`	`X`	`FRE`	`@0 Immunisation @5 05`
C03	`05`	`X`	`ENG`	`@0 Immunization @5 05`
C03	`05`	`X`	`SPA`	`@0 Inmunización @5 05`
C03	`06`	`X`	`FRE`	`@0 Vaccin @5 06`
C03	`06`	`X`	`ENG`	`@0 Vaccine @5 06`
C03	`06`	`X`	`SPA`	`@0 Vacuna @5 06`
C03	`07`	`X`	`FRE`	`@0 Vaccination @5 07`
C03	`07`	`X`	`ENG`	`@0 Vaccination @5 07`
C03	`07`	`X`	`SPA`	`@0 Vacunación @5 07`
C03	`08`	`X`	`FRE`	`@0 Liposome @5 09`
C03	`08`	`X`	`ENG`	`@0 Liposome @5 09`
C03	`08`	`X`	`SPA`	`@0 Liposoma @5 09`
C03	`09`	`X`	`FRE`	`@0 Polyprotéine @5 11`
C03	`09`	`X`	`ENG`	`@0 Polyprotein @5 11`
C03	`09`	`X`	`SPA`	`@0 Polyproteina @5 11`
C03	`10`	`X`	`FRE`	`@0 Prévention @5 12`
C03	`10`	`X`	`ENG`	`@0 Prevention @5 12`
C03	`10`	`X`	`SPA`	`@0 Prevención @5 12`
C03	`11`	`X`	`FRE`	`@0 Immunoprophylaxie @5 13`
C03	`11`	`X`	`ENG`	`@0 Immunoprophylaxis @5 13`
C03	`11`	`X`	`SPA`	`@0 Inmunoprofilaxia @5 13`
C03	`12`	`X`	`FRE`	`@0 Immunité cellulaire @5 14`
C03	`12`	`X`	`ENG`	`@0 Cellular immunity @5 14`
C03	`12`	`X`	`SPA`	`@0 Inmunidad celular @5 14`
C03	`13`	`X`	`FRE`	`@0 Composé conjugué @5 15`
C03	`13`	`X`	`ENG`	`@0 Conjugated compound @5 15`
C03	`13`	`X`	`SPA`	`@0 Compuesto conjugado @5 15`
C03	`14`	`X`	`FRE`	`@0 Protéine non structurale @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`05`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`06`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`06`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`06`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`07`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`07`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`07`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`08`	`X`	`FRE`	`@0 Pathologie des poumons @5 38`
C07	`08`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`08`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 341`

Format Inist (serveur)

NO :	PASCAL 09-0466845 INIST
ET :	Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a
AU :	KOHYAMA (Shunsuke); OHNO (Satoshi); SUDA (Tatsuya); TANEICHI (Maiko); YOKOYAMA (Shoichi); MORI (Masahito); KOBAVASHI (Akiharu); HAVASHI (Hidenori); UCHIDA (Tetsuva); MATSUI (Masanori)
AF :	Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho/Iruma-gun, Saitama 350-0495/Japon (1 aut., 2 aut., 3 aut., 10 aut.); Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University/Sakado-city, Saitama 350-0295/Japon (1 aut., 2 aut., 8 aut.); Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases/Musashimurayama-city, Tokyo 208-0011/Japon (4 aut., 9 aut.); Drug Delivery System Development Division, Nippon Oil and Fat Corporation/Tokyo 150-6019/Japon (5 aut., 6 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antiviral research; ISSN 0166-3542; Coden ARSRDR; Pays-Bas; Da. 2009; Vol. 84; No. 2; Pp. 168-177; Bibl. 1 p.
LA :	Anglais
EA :	Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A^0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8⁺ T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8⁺ T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A^0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.
CC :	002B02S05; 002B05C02C
FD :	Induction; Lymphocyte T cytotoxique; Syndrome respiratoire aigu sévère; Virus syndrome respiratoire aigu sévère; Immunisation; Vaccin; Vaccination; Liposome; Polyprotéine; Prévention; Immunoprophylaxie; Immunité cellulaire; Composé conjugué; Protéine non structurale
FG :	Virose; Infection; Coronavirus; Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Pathologie des poumons
ED :	Induction; Cytotoxic T lymphocyte; Severe acute respiratory syndrome; Severe acute respiratory syndrome virus; Immunization; Vaccine; Vaccination; Liposome; Polyprotein; Prevention; Immunoprophylaxis; Cellular immunity; Conjugated compound
EG :	Viral disease; Infection; Coronavirus; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease
SD :	Inducción; Linfocito T citotóxico; Síndrome respiratorio agudo severo; Severe acute respiratory syndrome virus; Inmunización; Vacuna; Vacunación; Liposoma; Polyproteina; Prevención; Inmunoprofilaxia; Inmunidad celular; Compuesto conjugado
LO :	INIST-18839.354000170327240070
ID :	09-0466845

Links to Exploration step

Pascal:09-0466845

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</title>
<author><name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name>
<affiliation><inist:fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name>
<affiliation><inist:fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kobavashi, Akiharu" sort="Kobavashi, Akiharu" uniqKey="Kobavashi A" first="Akiharu" last="Kobavashi">Akiharu Kobavashi</name>
<affiliation><inist:fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Havashi, Hidenori" sort="Havashi, Hidenori" uniqKey="Havashi H" first="Hidenori" last="Havashi">Hidenori Havashi</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Uchida, Tetsuva" sort="Uchida, Tetsuva" uniqKey="Uchida T" first="Tetsuva" last="Uchida">Tetsuva Uchida</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0466845</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0466845 INIST</idno>
<idno type="RBID">Pascal:09-0466845</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000176</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</title>
<author><name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name>
<affiliation><inist:fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name>
<affiliation><inist:fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kobavashi, Akiharu" sort="Kobavashi, Akiharu" uniqKey="Kobavashi A" first="Akiharu" last="Kobavashi">Akiharu Kobavashi</name>
<affiliation><inist:fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Havashi, Hidenori" sort="Havashi, Hidenori" uniqKey="Havashi H" first="Hidenori" last="Havashi">Hidenori Havashi</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Uchida, Tetsuva" sort="Uchida, Tetsuva" uniqKey="Uchida T" first="Tetsuva" last="Uchida">Tetsuva Uchida</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cellular immunity</term>
<term>Conjugated compound</term>
<term>Cytotoxic T lymphocyte</term>
<term>Immunization</term>
<term>Immunoprophylaxis</term>
<term>Induction</term>
<term>Liposome</term>
<term>Polyprotein</term>
<term>Prevention</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Induction</term>
<term>Lymphocyte T cytotoxique</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Immunisation</term>
<term>Vaccin</term>
<term>Vaccination</term>
<term>Liposome</term>
<term>Polyprotéine</term>
<term>Prévention</term>
<term>Immunoprophylaxie</term>
<term>Immunité cellulaire</term>
<term>Composé conjugué</term>
<term>Protéine non structurale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A<sup>*</sup>
0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8<sup>+</sup>
 T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8<sup>+</sup>
 T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A<sup>*</sup>
0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>84</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KOHYAMA (Shunsuke)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OHNO (Satoshi)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SUDA (Tatsuya)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TANEICHI (Maiko)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>YOKOYAMA (Shoichi)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MORI (Masahito)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KOBAVASHI (Akiharu)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HAVASHI (Hidenori)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>UCHIDA (Tetsuva)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MATSUI (Masanori)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>168-177</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000170327240070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0466845</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A<sup>*</sup>
0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8<sup>+</sup>
 T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8<sup>+</sup>
 T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A<sup>*</sup>
0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Induction</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Induction</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Inducción</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lymphocyte T cytotoxique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cytotoxic T lymphocyte</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Linfocito T citotóxico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunisation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunization</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunización</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Liposome</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Liposome</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Liposoma</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Polyprotéine</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Polyprotein</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Polyproteina</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Prévention</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Prevention</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Prevención</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Immunoprophylaxie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Immunoprophylaxis</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Immunité cellulaire</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Cellular immunity</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Inmunidad celular</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Composé conjugué</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Conjugated compound</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Compuesto conjugado</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Protéine non structurale</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie des poumons</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>341</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 09-0466845 INIST</NO>
<ET>Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</ET>
<AU>KOHYAMA (Shunsuke); OHNO (Satoshi); SUDA (Tatsuya); TANEICHI (Maiko); YOKOYAMA (Shoichi); MORI (Masahito); KOBAVASHI (Akiharu); HAVASHI (Hidenori); UCHIDA (Tetsuva); MATSUI (Masanori)</AU>
<AF>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho/Iruma-gun, Saitama 350-0495/Japon (1 aut., 2 aut., 3 aut., 10 aut.); Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University/Sakado-city, Saitama 350-0295/Japon (1 aut., 2 aut., 8 aut.); Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases/Musashimurayama-city, Tokyo 208-0011/Japon (4 aut., 9 aut.); Drug Delivery System Development Division, Nippon Oil and Fat Corporation/Tokyo 150-6019/Japon (5 aut., 6 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral research; ISSN 0166-3542; Coden ARSRDR; Pays-Bas; Da. 2009; Vol. 84; No. 2; Pp. 168-177; Bibl. 1 p.</SO>
<LA>Anglais</LA>
<EA>Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A<sup>*</sup>
0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8<sup>+</sup>
 T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8<sup>+</sup>
 T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A<sup>*</sup>
0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.</EA>
<CC>002B02S05; 002B05C02C</CC>
<FD>Induction; Lymphocyte T cytotoxique; Syndrome respiratoire aigu sévère; Virus syndrome respiratoire aigu sévère; Immunisation; Vaccin; Vaccination; Liposome; Polyprotéine; Prévention; Immunoprophylaxie; Immunité cellulaire; Composé conjugué; Protéine non structurale</FD>
<FG>Virose; Infection; Coronavirus; Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Pathologie des poumons</FG>
<ED>Induction; Cytotoxic T lymphocyte; Severe acute respiratory syndrome; Severe acute respiratory syndrome virus; Immunization; Vaccine; Vaccination; Liposome; Polyprotein; Prevention; Immunoprophylaxis; Cellular immunity; Conjugated compound</ED>
<EG>Viral disease; Infection; Coronavirus; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease</EG>
<SD>Inducción; Linfocito T citotóxico; Síndrome respiratorio agudo severo; Severe acute respiratory syndrome virus; Inmunización; Vacuna; Vacunación; Liposoma; Polyproteina; Prevención; Inmunoprofilaxia; Inmunidad celular; Compuesto conjugado</SD>
<LO>INIST-18839.354000170327240070</LO>
<ID>09-0466845</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000176 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000176 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0466845
   |texte=   Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a

Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri